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Reduction of adverse eﬀ ects from intravenous acetylcysteine 
treatment for paracetamol poisoning: a randomised 
controlled trial
D Nicholas Bateman, James W Dear, H K Ruben Thanacoody, Simon H L Thomas, Michael Eddleston, Euan A Sandilands, Judy Coyle, 
Jamie G Cooper, Aryelly Rodriguez, Isabella Butcher, Steﬀ  C Lewis, A D Bastiaan Vliegenthart, Aravindan Veiraiah, David J Webb, Alasdair Gray
Summary
Background Paracetamol poisoning is common worldwide. It is treated with intravenous acetylcysteine, but the 
standard regimen is complex and associated with frequent adverse eﬀ ects related to concentration, which can cause 
treatment interruption. We aimed to ascertain whether adverse eﬀ ects could be reduced with either a shorter modiﬁ ed 
acetylcysteine schedule, antiemetic pretreatment, or both.
Methods We undertook a double-blind, randomised factorial study at three UK hospitals, between Sept 6, 2010, and 
Dec 31, 2012. We randomly allocated patients with acute paracetamol overdose to either the standard intravenous 
acetylcysteine regimen (duration 20·25 h) or a shorter (12 h) modiﬁ ed protocol, with or without intravenous 
ondansetron pretreatment (4 mg). Masking was achieved by infusion of 5% dextrose (during acetylcysteine delivery) 
or saline (for antiemetic pretreatment). Randomisation was done via the internet and included a minimisation 
procedure by prognostic factors. The primary outcome was absence of vomiting, retching, or need for rescue 
antiemetic treatment at 2 h. Prespeciﬁ ed secondary outcomes included a greater than 50% increase in alanine 
aminotransferase activity over the admission value. Analysis was by intention to treat. This trial is registered with 
ClinicalTrials.gov (identiﬁ er NCT01050270).
Findings Of 222 patients who underwent randomisation, 217 were assessable 2 h after the start of acetylcysteine 
treatment. Vomiting, retching, or need for rescue antiemetic treatment at 2 h was reported in 39 of 108 patients 
assigned to the shorter modiﬁ ed protocol compared with 71 of 109 allocated to the standard acetylcysteine regimen 
(adjusted odds ratio 0·26, 97·5% CI 0·13–0·52; p<0·0001), and in 45 of 109 patients who received ondansetron 
compared with 65 of 108 allocated placebo (0·41, 0·20–0·80; p=0·003). Severe anaphylactoid reactions were recorded 
in ﬁ ve patients assigned to the shorter modiﬁ ed acetylcysteine regimen versus 31 who were allocated to the standard 
protocol (adjusted common odds ratio 0·23, 97·5% CI 0·12–0·43; p<0·0001). The proportion of patients with a 50% 
increase in alanine aminotransferase activity did not diﬀ er between the standard (9/110) and shorter modiﬁ ed (13/112) 
regimens (adjusted odds ratio 0·60, 97·5% CI 0·20–1·83); however, the proportion was higher with ondansetron 
(16/111) than with placebo (6/111; 3·30, 1·01–10·72; p=0·024). 
Interpretation In patients with paracetamol poisoning, a 12 h modiﬁ ed acetylcysteine regimen resulted in less 
vomiting, fewer anaphylactoid reactions, and reduced need for treatment interruption. This study was not powered to 
detect non-inferiority of the shorter protocol versus the standard approach; therefore, further research is needed to 
conﬁ rm the eﬃ  cacy of the 12 h modiﬁ ed acetylcysteine regimen.
Funding Chief Scientist Oﬃ  ce of the Scottish Government.
Introduction
Overdose of paracetamol (acetaminophen) is common, 
and the drug is the most frequent cause of acute 
liver failure in Europe and North America.1,2 During 
2011–12, more than 38 000 admissions for paracetamol 
poisoning were recorded in England3 and, in 2011, 
at least 137 000 enquiries were made to US poisons 
centres about paracetamol exposure.4 The toxic 
mechanisms of paracetamol—understood for more 
than 40 years—enabled development of a speciﬁ c 
antidote, acetylcysteine, in the 1970s.5–7 Intravenous 
regimens5 are now in widespread use, with between 
18 000 and 40 000 treatment courses administered in 
the UK annually.8 However, these regimens have never 
under gone formal dose-ranging studies.9 In particular, 
little attention has been paid to the initial dose regimen, 
which might cause dose-related vomiting in up to 60% of 
patients and anaphylactoid reactions leading to treatment 
interruption and refusal in a further 20%.10–12
The acetylcysteine regimen, although slightly variable 
worldwide, is universally complex; it includes three, 
separate, weight-related infusions over diﬀ erent 
timeframes, with a resultant high risk of medication 
error.13–15 Until September, 2012, the standard regimen for 
acetylcysteine used in the UK delivered 50% of the total 
dose over the ﬁ rst 15 min, rather than over a period of 1 h 
as with the US dosing schedule (panel 1).16 Although a 
higher frequency of dose-related adverse reactions might 
Published Online
November 28, 2013
http://dx.doi.org/10.1016/
S0140-6736(13)62062-0
See Online/Comment
http://dx.doi.org/10.1016/
S0140-6736(13)62303-X
This online publication has been 
corrected. The corrected version 
ﬁ rst appeared at thelancet.com 
on December 9, 2013
Copyright © Bateman et al. Open 
Access article distributed under 
the terms of CC BY
National Poisons Information 
Service, Royal Inﬁ rmary of 
Edinburgh, Edinburgh, UK 
(D N Bateman MD, J W Dear PhD, 
M Eddleston PhD, 
E A Sandilands MB, 
A Veiraiah MB); British Heart 
Foundation Centre for 
Cardiovascular Science, 
Edinburgh University, 
Edinburgh, UK (J W Dear, 
M Eddleston, 
A D B Vliegenthart BSc, 
Prof D J Webb DSc); Institute of 
Cellular Medicine, Newcastle 
University, and Newcastle 
Hospitals NHS Foundation 
Trust, Newcastle upon Tyne, UK 
(H K R Thanacoody MD, 
S H L Thomas MD); Emergency 
Medicine Research Group, 
Department of Emergency 
Medicine, Royal Inﬁ rmary of 
Edinburgh, Edinburgh, UK 
(J Coyle BSc, A Gray MD); 
Emergency Department, 
Aberdeen Royal Inﬁ rmary, 
Aberdeen, UK (J G Cooper MB); 
and Edinburgh Clinical Trials 
Unit (A Rodriguez MSc), and 
Centre for Population Health 
Sciences (I Butcher PhD, 
S C Lewis PhD), University of 
Edinburgh, Edinburgh, UK
Correspondence to:
Prof D Nicholas Bateman, 
National Poisons Information 
Service, Royal Inﬁ rmary of 
Edinburgh, Edinburgh EH16 4SA, 
UK
spib@luht.scot.nhs.uk
Articles
2 www.thelancet.com   Published online November 28, 2013   http://dx.doi.org/10.1016/S0140-6736(13)62062-0
be expected with this faster infusion rate, no diﬀ erences 
have been noted between these two initial doses.17 The 
total duration of the infusion is between 20·25 h and 21 h 
for these regimens.
We postulated that the incidence of adverse eﬀ ects 
reported with acetylcysteine treatment could be reduced 
with a simpler regimen that delivers the same total dose 
but over a shorter (12 h) period and with a lower, slower 
initial infusion dose (panel 1).16 Monte Carlo modelling 
based on published data from patients indicates that 
acetylcysteine concentrations at 20·25 h would be similar 
with the two regimens.18,19 Therefore, we did a factorial 
study to compare the rates of adverse reactions—with 
and without antiemetic pretreatment—between the 
standard acetylcysteine protocol and a shorter (12 h) 
modiﬁ ed schedule.
Methods
Participants
The study methods have been reported in full elsewhere.19 
In summary, we did a double-blind, randomised controlled 
trial at three acute clinical units in the UK, initially at the 
Royal Inﬁ rmary in Edinburgh and the Royal Victoria 
Inﬁ rmary, Newcastle, and subsequently at Aberdeen Royal 
Inﬁ rmary, to ensure adequate recruitment within the 
funding timeframe. Recruitment started on Sept 6, 2010, 
and ended on Dec 31, 2012. Patients were eligible for the 
study if they presented after an acute paracetamol 
overdose and needed treatment with acetylcysteine, on the 
basis of standard UK guidance for management.16,19 
Exclusion criteria are shown in ﬁ gure 1 and described 
elsewhere.19 We obtained ethics and regulatory approval 
for the study. Trained clinician recruiters obtained 
informed consent from all patients before trial entry.
Procedures
We treated patients who presented within 8 h of 
paracetamol ingestion on the basis of their measured 
paracetamol concentration in plasma. Individuals who 
presented more than 8 h after ingestion were managed 
initially according to the history of the ingested dose, but 
subsequently we withdrew them from the study if 
measured concentrations of paracetamol in plasma were 
below standard UK treatment lines (200 mg/L or 
100 mg/L at 4 h, depending on risk assessment). When 
clinically indicated, we administered further doses of 
acetylcysteine after completion of the initial schedule, 
according to standard UK practice.16 We pretreated all 
patients with either intravenous ondansetron (4 mg) or a 
matched placebo (saline), then we administered either 
the UK standard acetylcysteine regimen or the shorter 
(12 h) version (panel 1).16
We recorded adverse events in the patient’s clinical 
record and extracted data to the case report form. 
We also noted the use and timing of rescue drugs; 
we used intravenous cyclizine as antiemetic rescue and, 
initially, intravenous chlorphenamine for anaphylactoid 
symptoms. We allowed use of other treatments when 
clinically indicated, and we recorded these in the clinical 
record. The research team gathered outcome and survival 
data via the electronic system at every hospital and 
clinical notes, and they recorded this information in the 
case report form. We also obtained data from a sample of 
patients to assess acetylcysteine concentrations in the 
two regimens, and these will be reported separately.
We made two major protocol amendments. First, we 
extended the time allowed for ingestion of paracetamol 
from 1 h to 2 h to assist recruitment, because in practice 
many patients were found to ingest large single overdoses 
over a period up to 2 h. Second, after new UK guidance 
was issued in September, 2012,19,20 we used the 100 mg/L 
paracetamol nomogram line for recruitment of all 
patients. We established a data monitoring committee 
that met about every 6 months; they were aware of and 
supported all protocol modiﬁ cations and made no other 
changes to the study.
Randomisation and masking
We used a 2×2 factorial trial design, which included four 
parallel groups: ondansetron pretreatment and the 
shorter acetylcysteine regimen (ondansetron-modiﬁ ed); 
ondansetron and the standard schedule (ondansetron-
standard); placebo and the shorter acetylcysteine protocol 
(placebo-modiﬁ ed); and placebo and the standard 
regimen (placebo-standard). We did randomisation by 
minimisation to achieve balance (1:1:1:1 allocation), 
according to the following prognostic factors: reported 
paracetamol dose (<16 g or ≥16 g); risk factors for 
paracetamol-induced hepatic toxic eﬀ ects; and time to 
presentation (<8 h or ≥8 h).16 We used an online program 
for the randomisation, which was provided by the 
Edinburgh Clinical Trials Unit, thus ensuring allocation 
concealment. To achieve masking, ondansetron and 
saline placebo ampoules were identical in appearance, 
but because of ethical and practical concerns, we could 
not mask the administering team to the acetylcysteine 
regimen. Patients allocated to the shorter modiﬁ ed 
acetylcysteine regimen received intravenous 5% dextrose 
after the full acetylcysteine dose was given, to ensure the 
total infusion time was the same in both groups.
Panel 1: Acetylcysteine regimens used in the study
UK standard schedule (duration 20·25 h)16
• 150 mg/kg in 200 mL, over 15 min
• 50 mg/kg in 0·5 L, over 4 h
• 100 mg/kg in 1 L, over 16 h
Modiﬁ ed (shorter) protocol (duration 12 h)
• 100 mg/kg in 200 mL, over 2 h
• 200 mg/kg in 1 L, over 10 h
• 0·5 L of 5% dextrose, to 20·25 h
Acetylcysteine is administered in 5% dextrose.
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Outcome measures
The primary outcome, deﬁ ned a priori, was the 
proportion of patients who did not vomit or retch and did 
not need rescue antiemetic drugs—as assessed by 
clinical case records and patients’ self-reporting—within 
2 h of initiation of acetylcysteine.19 For clarity, this 
outcome measure is reported in terms of treatment 
beneﬁ t (ie, symptom presence, need to treat, or both).
We assessed secondary outcomes up to 12 h after 
the start of treatment. Secondary outcomes were: 
the proportion of patients without nausea (Likert scale 
<5 of 11), vomiting, or retching up to 12 h after initiation 
of acetylcysteine treatment (for clarity, expressed 
as treatment beneﬁ t); and occurrence of anaphy -
lactoid reactions, which was judged by the need for 
treatment or acetylcysteine interruption for an 
anaphylactoid response, by self-reported ﬂ ushing, 
itchy skin, skin rash, chest pain, breathlessness, wheeze, 
and tongue or lip swelling (all assessed on Likert scales, 
>4 of 11), and by recorded changes in blood pressure 
(fall of systolic >20 mm Hg) and pulse rate 
(rise of >20 bpm). We categorised the severity of 
anaphylactoid reactions on a predeﬁ ned three-
grade severity scale.19,21 Grade 1 reactions (mild) were 
deﬁ ned either as a positive response in one of the 
domains on the Likert scales or as a change in blood 
pressure or pulse rate (as described). Grade 2 reactions 
(moderate) fulﬁ lled either two or more positive 
symptom domains on the Likert scales, cardio vascular 
changes (blood pressure or pulse), or both, but with 
no requirement for speciﬁ c treatment or stopping 
acetylcysteine treatment. Grade 3 reactions (severe) 
included patients who either had acetyl cysteine treatment 
interrupted, an intervention with an anti-allergy drug, 
or both.
We prespeciﬁ ed other analyses to assess the frequency 
of hepatic toxic eﬀ ects at the end of treatment (derived 
from case records), including a greater than 50% increase 
Figure 1: Trial proﬁ le
One patient had incomplete data at 2 h but completed the trial. *Other reasons for exclusion: unlikely to complete treatment (n=27), life-threatening illness (17), 
detained under the Mental Health Act (15), permanent cognitive impairment (9), pregnant (6), on anticoagulants (5); non-English speaking (4), unable to complete 
questionnaires (3), and history of hypersensitivity to serotonin antagonists (3).
3311 screened 
1772 not suitable for acetylcysteine treatment (57% of screened)
147 no clinician available to consent
1539 judged suitable for acetylcysteine 
  treatment (43% of screened)
369 eligible
222 randomised (67% of eligible)
1170 excluded (fulfilled exclusion criteria, or other reason for 
 non-participation)
 490 staggered overdose
 146 intoxicated, unable to consent
 116 presented beyond recruitment interval
 90 unreliable history
 69 vomiting requiring antiemetic before randomisation
 60 refusals
 57 previous participant in trial
 89 other prespecified exclusion*
 53 other reasons (eg, self-discharged)
55 ondansetron-modified
 54 received treatment
 1 withdrawn pretreatment
56 ondansetron-standard
 55 received treatment
 1 withdrawn pretreatment
55 placebo-modified
 55 received treatment
56 placebo-standard
 54 received treatment
 2 withdrawn pretreatment
 51 completed treatment
 1 withdrawn pretreatment
 2 lost after 2 h
 1 lost after 12 h
 49 completed treatment
 1 withdrawn pretreatment
 2 lost after 2 h
 2 lost after 4 h
 2 lost after 12 h
 51 completed treatment
 2 lost after 2 h
 2 lost after 12 h
 52 completed treatment
 2 withdrawn pretreatment
 2 lost after 2 h
 54 analysed in primary outcome
 1 withdrawn pretreatment
 55 analysed in primary outcome
 1 withdrawn pretreatment
 54 analysed in primary outcome
 1 data not collected
 54 analysed in primary outcome
 2 withdrawn pretreatment
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in alanine aminotransferase activity over the admission 
value and activity of alanine aminotransferase greater 
than 1000 IU/L. We also recorded, at 20·25 h after 
initiation of acetylcysteine, when the international 
normalised ratio rose to more than 1·3, although this 
measurement can potentially be confounded by 
acetylcysteine.11,22 Finally, in a subset of Edinburgh 
patients, we did a post-hoc analysis of microRNA 
miR-122, which is a sensitive and speciﬁ c marker of 
hepatic injury.23,24
Statistical analysis
To achieve at least 80% power to detect a relative risk of 
0·6 for the proportion of patients with vomiting within 
2 h (from 60% in the placebo group to 36% in the treated 
group), we needed to enrol 91 patients on ondansetron 
and 91 on placebo (p=0·025). This number was increased 
to allow for dropouts and to ensure we included 
50 patients in each of the four groups in the factorial 
study.19 To account for the factorial design, we used a 
signiﬁ cance level of 2·5%, and we calculated 97·5% CIs. 
All applicable statistical tests were two-sided.
The analysis was done according to randomised 
treatment group, irrespective of adherence to treatment 
(intention to treat). Because of the trial design and the 
need to recruit late-presenting patients before data for 
paracetamol concentration were available, we subse-
quently excluded some individuals (ﬁ gure 1); data 
collection and follow-up were stopped after treatment 
discontinuation for any reason. If patients had missing 
data for an outcome variable, we removed them from 
formal statistical analysis at that timepoint.
We analysed binary variables (including the primary 
outcome) with logistic regression, adjusting for prognostic 
factors included in the minimisation algorithm and for 
centre. Because we did a factorial trial, we entered the 
main eﬀ ect for both treatment comparisons into the 
model concurrently. We derived Kaplan-Meier plots for 
use of antiemetic or anaphylactic rescue medication from 
the start of the ﬁ rst infusion, by regimen and treatment. 
Acetylcysteine regimen Ondansetron pretreatment Ondansetron-
modiﬁ ed (n=55)
Ondansetron-
standard (n=56)
Placebo-
modiﬁ ed (n=55)
Placebo-
standard (n=56)
Modiﬁ ed (n=110) Standard (n=112) Active (n=111) Placebo (n=111)
Demographics
Centre
Edinburgh 75 (68%) 75 (67%) 74 (67%) 76 (68%) 37 (67%) 37 (66%) 38 (69%) 38 (68%)
Newcastle 26 (24%) 28 (25%) 27 (24%) 27 (24%) 13 (24%) 14 (25%) 13 (24%) 14 (25%)
Aberdeen 9 (8%) 9 (8%) 10 (9%) 8 (7%) 5 (9%) 5 (9%) 4 (7%) 4 (7%)
Median (IQR) age (years) 32 (22–47) 32 (22–45) 30 (21–44) 35 (26–47) 29 (20–44) 32 (22–45) 36 (25–49) 33 (27–46)
Median (IQR) weight (kg) 70 (60–84) 68 (60–80) 68 (57–83) 70 (62–80) 70 (55–86) 68 (60–81) 70 (63–83) 70 (60–80)
Women 64 (58%) 67 (60%) 65 (59%) 66 (59%) 31 (56%) 34 (61%) 33 (60%) 33 (59%)
Clinical characteristics
Time from ingestion to 
treatment, <8 h
64 (58%) 64 (57%) 65 (59%) 63 (57%) 32 (58%) 33 (59%) 32 (58%) 31 (55%)
Median (IQR) ingested 
paracetamol (mg/kg)
229 (167–328) 244 (184–357) 224 (167–327) 243 (169–353) 224 (168–333) 233 (184–312) 233 (169–308) 264 (182–417)
Ingested paracetamol ≥16 g 58 (53%) 58 (52%) 57 (51%) 59 (53%) 28 (51%) 29 (52%) 30 (55%) 29 (52%)
Nomogram at 4 h*
100–149 mg/L 22 (20%) 26 (23%) 28 (25%) 20 (18%) 12 (22%) 16 (29%) 10 (18%) 10 (18%)
150–199 mg/L 19 (17%) 18 (16%) 22 (20%) 15 (14%) 11 (20%) 11 (20%) 8 (15%) 7 (13%)
≥200 mg/L 35 (32%) 41 (37%) 41 (37%) 35 (32%) 21 (38%) 20 (36%) 14 (25%) 21 (38%)
Alcohol ingested 52 (47%) 59 (53%) 58 (52%) 53 (48%) 28 (51%) 30 (54%) 24 (44%) 29 (52%)
Other drugs ingested 56 (51%) 71 (63%) 57 (51%) 70 (63%) 25 (45%) 32 (57%) 31 (56%) 39 (70%)
Opiates 11 21 12 20 4 8 7 13
Antihistamines 4 1 3 2 3 0 1 1
Nutritional deﬁ ciency 15 (14%) 15 (13%) 17 (15%) 13 (12%) 8 (15%) 9 (16%) 7 (13%) 6 (11%)
Debilitating disease 3 (3%) 3 (3%) 2 (2%) 4 (4%) 1 (2%) 1 (2%) 2 (4%) 2 (4%)
Chronic alcohol use 37 (34%) 39 (35%) 35 (32%) 41 (37%) 16 (29%) 19 (34%) 21 (38%) 20 (36%)
Identiﬁ ed as high risk† 51 (46%) 52 (46%) 50 (45%) 53 (48%) 24 (44%) 26 (46%) 27 (49%) 26 (46%)
Median (IQR) alanine 
aminotransferase (IU/L)
20 (14–30) 20 (14–29) 21 (14–34) 19 (14–26) 21 (14–37) 21 (14–30) 19 (14–26) 19 (14–26)
Data are number of patients (%) or median (IQR). *Nomogram assessments are from the paracetamol risk nomogram for patients with paracetamol samples between 4 h and 24 h after ingestion. †According to 
the British National Formulary, 2009;16 no patients were taking enzyme-inducing drugs.
Table 1: Baseline characteristics
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We analysed grade of anaphylaxis with proportional odds 
logistic regression. We also did sensitivity analyses, 
unadjusted analyses, and analyses adjusting for the 
interaction between treatment groups, but none of these 
aﬀ ected the conclusions. For the microRNA analysis, we 
did two-way analysis of variance on log-transformed data.
This trial is registered with the European Clinical 
Trials Database (EudraCT number 2009-017800-10) and 
ClinicalTrials.gov (identiﬁ er NCT01050270).
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all 
study data and the corresponding author had respon s-
ibility for the decision to submit for publication.
Results
Between Sept 6, 2010, and Dec 31, 2012, 3311 patients 
presented with paracetamol overdose and were screened 
for inclusion in the study; 1539 were judged potentially 
suitable for acetylcysteine treatment, 369 were eligible 
for inclusion, and 222 underwent randomisation 
(ﬁ gure 1). Table 1 shows the number of patients at each 
participating centre and their baseline demographic 
features, according to treatment allocation. Groups were 
well balanced at baseline with respect to age, sex, weight, 
ingested paracetamol dose, paracetamol nomogram 
band, other risk factors for paracetamol hepatic toxic 
eﬀ ects, and other ingested agents (including opiates 
and antihistamines) or regular prescribed drugs. 
Of 19 patients who withdrew from the study before 
completion of treatment (ﬁ gure 1), 14 were below 
treatment lines and ﬁ ve refused to complete the study. 
No emergency unmasking took place.
Table 2 presents available outcome data for patients 
who had vomiting or retching or used rescue medi-
cation within 2 h of acetylcysteine initiation. This primary 
outcome was signiﬁ cantly less frequent in patients 
who received the shorter modiﬁ ed acetylcysteine regimen 
compared with those allocated to the standard 
schedule (adjusted odds ratio 0·26, 97·5% CI 0·13–0·52; 
p<0·0001) and in those treated with ondansetron 
versus placebo (0·41, 0·20–0·80; p=0·003). No inter-
action was noted between the two treatment comparisons 
(p=0·69).
The secondary outcome of nausea (Likert >4 of 11), 
vomiting, or retching up to 12 h after the start of treat-
ment was less common in patients who received the 
shorter modiﬁ ed acetylcysteine regimen compared with 
those who were allocated the standard protocol (adjusted 
odds ratio 0·37, 97·5% CI 0·18–0·79; p=0·003). Similarly, 
the treatment diﬀ erence was signiﬁ cant for those 
pretreated with ondansetron versus individuals who 
received placebo (0·35, 0·17–0·74; p=0·002). The Kaplan-
Meier plot for time to antiemetic rescue is shown in 
ﬁ gure 2.
Anaphylactoid symptoms were recorded in 133 (64%) 
of 208 patients overall, and these were classiﬁ ed as mild 
in 79 (38%), moderate in 18 (9%), and severe in 36 (17%). 
Anaphylactoid symptoms were absent in 50 (46%) of 
108 patients allocated to the shorter modiﬁ ed acetyl-
cysteine regimen and 25 (25%) of 100 who received the 
standard treatment. Fewer patients allocated to the 
shorter modiﬁ ed acetylcysteine regimen had clinically 
relevant grade 3 (severe) reactions needing either drug 
treatment or interruption of the acetylcysteine infusion 
(ﬁ ve of 108, ﬁ ve treated, two interrupted) compared with 
those assigned to the standard regimen (31 of 100, 
31 treated, 26 interrupted; adjusted common odds ratio 
Number 
with 
outcome
Total Adjusted data* Unadjusted data†
Odds ratio 
(97·5% CI)
p Odds ratio 
(97·5% CI)
p
Primary outcome‡
Acetylcysteine regimen
Modiﬁ ed 39 108 0·26 (0·13–0·52) <0·0001 0·29 (0·15–0·55) <0·0001
Standard 71 109 ·· ·· ·· ··
Ondansetron pretreatment
Active 45 109 0·41 (0·20–0·80) 0·003 0·43 (0·22–0·82) 0·004
Placebo 65 108 ·· .. ·· ··
Secondary outcome§
Acetylcysteine regimen
Modiﬁ ed 60 101 0·37 (0·18–0·79) 0·003 0·39 (0·19–0·80) 0·004
Standard 80 102 ·· ·· ·· ··
Ondansetron pretreatment
Active 58 99 0·35 (0·17–0·74) 0·002 0·37 (0·18–0·76) 0·002
Placebo 82 104 ·· ·· ·· ··
 *Adjusted by the variables in the minimisation algorithm, and centre. †Obtained with a model in which only treatment 
and regimen were included. ‡Patients with vomiting or retching or given rescue medication, from 0 h to 2 h. §Patients 
with vomiting or retching or nausea, from 0 h to 12 h.
Table 2: Primary and secondary nausea and vomiting outcomes
Figure 2: Kaplan-Meier plot of patients who did not need antiemetic rescue for 0–12 h, by treatment regimen
Number at risk
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0·23, 97·5% CI 0·12–0·43; p<0·0001); this ﬁ nding was 
not aﬀ ected by ondansetron pretreatment (17 of 103 vs 
19 of 105 on placebo; 1·40, 0·78–2·53; p=0·198). The 
Kaplan-Meier plot for time to anaphylactoid rescue is 
shown in ﬁ gure 3.
A 50% increase in activity of alanine amino transferase 
20·25 h after initiation of the acetylcysteine infusion was 
recorded in 22 (11%) of 201 patients, nine who were 
allocated to the standard acetyl cysteine regimen and 
13 of those assigned to the shorter modiﬁ ed schedule 
(adjusted odds ratio 0·60, 97·5% CI 0·20–1·83). This 
escalation in activity of alanine amino trans ferase was 
more frequent in patients pre treated with ondansetron 
(16 of 100) compared with those receiving placebo 
(six of 101; 3·30, 1·01–10·72; p=0·024; appendix p 1). 
An increased frequency in the doubling of alanine 
amino transferase (post-hoc analysis) was noted in 
patients pretreated with ondansetron (14 of 100) 
compared with those given placebo (ﬁ ve of 101; adjusted 
odds ratio 3·47, 97·5% CI 0·95–12·66; p=0·031). At the 
end of acetylcysteine infusion, ﬁ ve of 202 patients 
had activity of alanine aminotransferase greater than 
1000 IU/L (two ondansetron-modiﬁ ed, one ondansetron-
standard, two placebo-standard) and 25 of 201 people 
had an international normalised ratio higher than 1·3 
(seven ondansetron-modiﬁ ed, seven ondansetron-
standard, two placebo-modiﬁ ed, nine placebo-standard); 
no diﬀ erence was recorded between treatment allocations 
(appendix p 1). Six (6%) patients allocated to the shorter 
modiﬁ ed acetylcysteine regimen received additional 
acetyl cysteine infusions (post-hoc analysis) compared 
with 11 (10%) of those allocated to the standard schedule 
(adjusted odds ratio 0·46, 97·5% CI 0·13–1·68; p=0·180); 
12 (11%) patients assigned to ondansetron pretreatment 
received additional infusions of acetylcysteine compared 
with ﬁ ve (5%) of those who received placebo beforehand 
(2·82, 0·76–10·53; p=0·077). No patients developed acute 
kidney injury.
In a post-hoc analysis of miR-122 (normalised for 
hsa-let-7d-5p) in 124 patients from Edinburgh, no diﬀ er-
ence was apparent at the end of either of the acetylcysteine 
regimens (standard, median ΔΔCt 0·5 [IQR 0·2–3·4] vs 
modiﬁ ed, ΔΔCt 1·1 [0·4–2·4]; p=0·79). However, miR-122 
was higher in patients pretreated with ondansetron than 
those who received placebo (ΔΔCt 1·3 [0·4–3·4] vs ΔΔCt 
0·6 [0·2–2·0]; p=0·03).
A total of 174 adverse events were reported by 
170 participants across all groups. Most of these were 
expected reactions: 92 gastrointestinal and 13 hepato-
biliary. One patient died, an elderly man, who recovered 
from paracetamol overdose but died 20 days after the end 
of treatment from previously diagnosed malignant 
disease.
Discussion
The ﬁ ndings of our study show that a shorter (12 h) 
modiﬁ ed acetylcysteine regimen substantially reduces 
the frequency of both vomiting and serious anaphylactoid 
reactions when compared with the standard schedule for 
acetylcysteine administration (duration 20·25 h). The 
shorter duration of acetylcysteine infusion oﬀ ers simpler 
administration, a probable reduction in administration 
errors, and a potential decrease in the length of the 
hospital stay. However, further clinical trials and studies 
of novel23 and traditional25 biomarkers are needed to 
conﬁ rm the eﬃ  cacy and safety of the modiﬁ ed regimen 
before widespread adoption into clinical practice.
Vomiting was reduced by pretreatment with 
ondansetron, thus increasing the antiemetic beneﬁ t of 
the modiﬁ ed regimen, but this fall was associated with 
an unexpected increase in activity of aminotransferase. 
Potential mechanisms include either alterations in 
paracetamol metabolism or glutathione synthesis or a 
direct eﬀ ect of ondansetron on a stressed liver, although 
a type 1 error is possible. Although these eﬀ ects did not 
seem to be clinically important, further research is 
needed before ondansetron is used routinely for this 
indication.
Our study ﬁ ndings conﬁ rm that symptomatic adverse 
eﬀ ects, particularly vomiting and anaphylactoid reactions 
(panel 2), are associated commonly with the standard 
UK regimen for acetylcysteine administration. These 
events are unpleasant, result in treatment interruption 
and delay, and can cause patients to refuse or even 
be denied treatment in subsequent presentations.1 
Such eﬀ ects can be severe, with 28 (13%) patients in 
our trial having their treatment interrupted. Anaphy-
lactoid reactions occur most commonly at lower 
concentrations of paracetamol and, thus, are more 
likely to be seen in patients now treated under new 
UK guidance.8,12,29,30
Not all patients eligible for treatment with acetylcysteine 
were included in our study (ﬁ gure 1), mostly because of a 
staggered overdose, alcohol intoxication, or drowsiness. 
These exclusions are unlikely to aﬀ ect our main ﬁ ndings. 
Figure 3: Kaplan-Meier plot of patients who did not need treatment for anaphylactoid reactions for 0–12 h, 
by treatment regimen
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However, eﬃ  cacy and safety of the modiﬁ ed acetylcysteine 
regimen in staggered overdoses will need to be assessed.
Some patients who were included in our study initially 
were withdrawn later when paracetamol concentrations 
showed they did not need acetylcysteine. These 
individuals featured in the analysis if they were still 
receiving acetylcysteine at the time of primary outcome 
assessment. These factors are unlikely to aﬀ ect the 
generalisability of our results.
In view of the complexity of the standard acetylcysteine 
regimen, a double-blind comparison with the shorter 
modiﬁ ed protocol was not feasible. The potential regimens 
are complex, requiring either ﬁ ve infusions in the 
standard procedure (for 15 min, 1 h 45 min, 2 h 15 min, 
7 h 45 min, and 8 h 15 min) or two concurrent infusion 
regimens for every patient.
The open nature of the comparison might have led to 
observer bias in the assessment of adverse drug reactions. 
However, the primary outcome—the noted absence of 
vomiting, retching, and use of antiemetic rescue 
treatment—is objective, as is the measurement of 
concentrations of aminotransferases. Assessment of 
anaphylactoid reactions was made as objective as possible 
by use of a detailed scoring system, including patient 
self-rating at prespeciﬁ ed times.
Although our trial is, to our knowledge, the largest 
randomised controlled trial of paracetamol poisoning 
ever undertaken, it was not suﬃ  ciently powered to show 
non-inferiority of the modiﬁ ed acetylcysteine regimen 
for prevention of hepatotoxic eﬀ ects. We used a 50% 
increase in alanine aminotransferase concentration as a 
surrogate marker of liver damage, because more severe 
liver dysfunction is rare (although rises in the 
international normalised ratio and activity of alanine 
aminotransferase >1000 IU/L were also measured). 
Doubling of alanine aminotransferase and miR-122 
ﬁ ndings were similar for both acetylcysteine regimens, 
but both measurements were more frequently abnormal 
in patients administered ondansetron. We identiﬁ ed 
a large proportion of patients with no change in 
the amount of alanine aminotransferase and with 
paracetamol concentrations less than 20 mg/L at 12 h 
(appendix p 1). We believe this patient group could be 
discharged early, if ﬁ ndings of a larger study conﬁ rm the 
absence of inferiority.
The shorter modiﬁ ed acetylcysteine regimen caused 
signiﬁ cantly less nausea, vomiting, and anaphylactoid 
reactions, with diminished requirement for rescue treat-
ment. This approach oﬀ ers potentially major advantages 
for patients, staﬀ , and health-care institutions. Further 
research in larger numbers of patients is needed to 
conﬁ rm the eﬃ  cacy of the shorter acetylcysteine regimen.
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Panel 2: Research in context
Systematic review
We searched PubMed and the Cochrane Database for clinical 
trials and systematic reviews of acetylcysteine treatment for 
paracetamol overdose and antiemetic pretreatment published 
between January, 1975, and December, 2008, with the terms 
“paracetamol”, “acetaminophen”, “overdose”, “acetylcysteine”, 
and “anti-emetic”. In 2006, the Cochrane Collaboration 
published a systematic review of evidence for management of 
paracetamol overdose.26 The eﬃ  cacy of diﬀ erent oral and 
intravenous acetylcysteine regimens did not diﬀ er with respect 
to prevention of hepatotoxic eﬀ ects but these drugs were 
associated with adverse events such as vomiting and 
anaphylactoid reactions. The conclusion stated that the best 
method of administration of acetylcysteine and the most 
beneﬁ cial dose had not been reported. No published trials were 
identiﬁ ed of antiemetic prophylaxis before administration of 
intravenous acetylcysteine treatment. Although high-dose 
metoclopramide was eﬀ ective at prevention of emesis before 
oral acetylcysteine in one small study,27 this drug was 
associated with a high incidence of extrapyramidal adverse 
eﬀ ects in young adults, making it unsuitable for this patient 
group. For prophylaxis of nausea and vomiting in other 
settings (eg, postoperative), more trial evidence was available 
for eﬃ  cacy of ondansetron than for other antiemetics, in a 
Cochrane Collaboration systematic review.28 Our search did not 
identify any studies that have addressed the need for 
treatment interruption because of adverse events.
Interpretation
We have shown in our study that a 12 h intravenous regimen 
of acetylcysteine, with an initial loading dose over 2 h, is 
eﬀ ective at reducing the incidence of vomiting and 
anaphylactoid reactions, compared with the standard 20·25 h 
intravenous acetylcysteine schedule. Our trial was not powered 
to assess non-inferiority of the modiﬁ ed protocol, but no 
diﬀ erence in eﬃ  cacy was recorded between groups. 
Ondansetron pretreatment was eﬀ ective at reducing vomiting 
but had no eﬀ ect on anaphylactoid reactions and was 
associated with a rise in the amount of aminotransferase. 
Other key advantages of the 12 h regimen include simplicity 
and substantial reductions in the need to treat anaphylactoid 
reactions and to interrupt the acetylcysteine infusion because 
of adverse eﬀ ects, both of which complicate and prolong 
hospital care. This shorter and simpler protocol, if proven to be 
non-inferior to the conventional acetylcysteine regimen, has 
considerable potential to reduce adverse eﬀ ects and length of 
hospital stay in patients requiring acetylcysteine treatment 
after a paracetamol overdose.
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